Literature DB >> 23750877

A deletion in the wapB promoter in many serotypes of Pseudomonas aeruginosa accounts for the lack of a terminal glucose residue in the core oligosaccharide and resistance to killing by R3-pyocin.

Dana Kocíncová1, Joseph S Lam.   

Abstract

Pseudomonas aeruginosa is an opportunistic human pathogen producing a variety of virulence factors. One of them is lipopolysaccharide, consisting of endotoxic lipid A and long-chain O-antigen polysaccharide, which are connected together through a short linker region, called core oligosaccharide. Chemical structures of the core oligosaccharide are well conserved, with one exception, in that certain strains of P. aeruginosa add a terminal glucose residue (Glc(IV) ) to core by a transferase reaction, due to the activity of a glucosyltransferase, WapB. Here, we investigated the regulation of wapB expression. Our results showed that while the majority of analysed genomes of P. aeruginosa contain wapB, many of these have a conserved identical 5-nucleotide deletion in the upstream region that inactivated the promoter. This deletion is within the -10 hexamer that is recognized by a principle sigma factor (RpoD, or σ70) as proven by data from an electromobility shift assay. These results provide the molecular basis of why LPS core of many P. aeruginosa strains is lacking Glc(IV) . In addition, we show that absence of Glc(IV) due to an inactive wapB promoter confers resistance to killing by R3-pyocin, a phage tail-like bacteriocin of P. aeruginosa.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750877     DOI: 10.1111/mmi.12289

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  9 in total

1.  Single-Nucleotide Polymorphisms Found in the migA and wbpX Glycosyltransferase Genes Account for the Intrinsic Lipopolysaccharide Defects Exhibited by Pseudomonas aeruginosa PA14.

Authors:  Youai Hao; Kathleen Murphy; Reggie Y Lo; Cezar M Khursigara; Joseph S Lam
Journal:  J Bacteriol       Date:  2015-06-15       Impact factor: 3.490

2.  Heterogenous Susceptibility to R-Pyocins in Populations of Pseudomonas aeruginosa Sourced from Cystic Fibrosis Lungs.

Authors:  Madeline Mei; Jacob Thomas; Stephen P Diggle
Journal:  mBio       Date:  2021-05-04       Impact factor: 7.867

3.  Systematic discovery of pseudomonad genetic factors involved in sensitivity to tailocins.

Authors:  Sean Carim; Ashley L Azadeh; Alexey E Kazakov; Morgan N Price; Peter J Walian; Lauren M Lui; Torben N Nielsen; Romy Chakraborty; Adam M Deutschbauer; Vivek K Mutalik; Adam P Arkin
Journal:  ISME J       Date:  2021-03-01       Impact factor: 11.217

4.  Crystal Structures of R-Type Bacteriocin Sheath and Tube Proteins CD1363 and CD1364 From Clostridium difficile in the Pre-assembled State.

Authors:  Nina Schwemmlein; Jan Pippel; Emerich-Mihai Gazdag; Wulf Blankenfeldt
Journal:  Front Microbiol       Date:  2018-08-03       Impact factor: 5.640

5.  R pyocin tail fiber structure reveals a receptor-binding domain with a lectin fold.

Authors:  Adam J Salazar; Mukul Sherekar; Jennifer Tsai; James C Sacchettini
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

6.  The therapeutic potential of bacteriocins as protein antibiotics.

Authors:  Hannah M Behrens; Anne Six; Daniel Walker; Colin Kleanthous
Journal:  Emerg Top Life Sci       Date:  2017-04-21

7.  Different Ancestries of R Tailocins in Rhizospheric Pseudomonas Isolates.

Authors:  Maarten G K Ghequire; Yörg Dillen; Ivo Lambrichts; Paul Proost; Ruddy Wattiez; René De Mot
Journal:  Genome Biol Evol       Date:  2015-09-26       Impact factor: 3.416

Review 8.  Lectin-Like Bacteriocins.

Authors:  Maarten G K Ghequire; Başak Öztürk; René De Mot
Journal:  Front Microbiol       Date:  2018-11-12       Impact factor: 5.640

Review 9.  The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology.

Authors:  Steven M Huszczynski; Joseph S Lam; Cezar M Khursigara
Journal:  Pathogens       Date:  2019-12-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.